OMICS Group International is all set to organize 3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials in Hyderabad. It will be held from October 27-29 this year at Hyderabad International Convention Centre, Hyderabad.
Pharmacovigilance is also known as Drug Safety, It is the Pharmacological Science relating to the collection, detection, assessment, monitoring and prevention of adverse effects with pharmaceutical products.
AdvertisementThe theme of the conference is "Safer Drugs to Market by Analyzing Latest Developments in Pharmacovigilance, Drug Safety and Risk Management", informed Dr. Srinubabu Gedela, Managing Director of OMICS Group
Pharmacovigilance and all drug safety issues are relevant for everyone whose life is touched in any way by medical interventions, informed Dr. Srinubabu Gedela.
Recently, its concerns have been widened to include herbals, traditional and complementary medicines, blood products, biologicals, medical devices and vaccines. Substandard medicines, medication errors, lack of efficacy reports, use of medicines for indications that are not approved and for which there is inadequate scientific basis, case reports of acute and chronic poisoning, abuse and misuse of medicines are some of the concerns of the whole world. Conference like this addresses issues and helps industry find out solutions informed Anil of OMICS
The Curtain Raiser press conference was also addressed by Dr. Malla Reddy, Prof Emiraturs of All India Council of Technical Education ; Dr. M. Venkata Reddy, Director, Hitech Institute of Advance Pharmaceutical Sciences; Dr Ravi Kanneti, Manager, Dr. Reddys Laboratories Ltd.; Mr S V Krishna Prasad, CEO & Director, Cito Healthcare (P) Ltd.
Speaking on the occasionDr. Malla Reddy said, Pharmcovigilance is a very important subject. It is in its nascent stage in India. Until sometime ago Hyderabad used to be the Bulk Drug Capital. Similarly, we all though Hyderabad would also become a Hub for Clinical Trials. But, unfortunately due to irresponsible communication and bad publicity, we could never become. Samll countries like Singapore, Malaysia reaped rich awards out of Clinical Trials.
Media misled people about Clinical Trials. There could be few stray incident which were not very good for industry, but, due to bad publicity, we have lost a great opportunity. If a lakh clinical trials happen in America, not even 2000 Clinical Trials happen in India, he said. He want government and media to create awareness about Pharmacovigilance.
Dr. Malla Reddy wanted Governments to appoint qualified pharmacists in hospitals and drug stores to explain the contents of the drug.
Dr. Venkat Reddy said every medicine is a useful poision. It works well if taken in right does. If there is any variation, it works adversely. It takes 12 to 15years before a new drug is introduced in the market. For every drug to get evolved and accepted it needs so much time for series of tests to prove its efficacy. And Pharma Companies spend anywhere in the range of Rs 300 to 500 crore to develop and introduce a new drug. From 1960 till now 150 drugs were taken back from the market due to their adverse reactions. Due to which Rs 7500 core spent on developing these drugs has gone down the drain, he observed.
Pharmacovigilance is just ten years old in this country. 3 to 5 per cent of those who are hospitalized are due to adverse reaction of the drug. People are not aware who to complain in such cases. Media plays a vital role creating awareness. Let people come forward and report such cases. Even we don't find prescription audit in India
Over the last couple of decades, advances in biomedical science have generated more new and complex medicines to treat a broader range of diseases and conditions than ever before. The number of people taking medications has increased dramatically, and, as a result, governments, patient groups and health advocates are demanding stronger regulatory practices and procedures, to assure the safety of medicines before and after they reach the market.
Hence, as the regulatory landscape continues to evolve it is crucial that a professional keeps abreast of the changes impacting the drug safety industry to ensure that their pharmacovigilance strategies are robust and geared to compliance. In addition to this effective risk management and minimisation efforts and comprehensive benefit: risk analysis of drugs must lay the foundations for a strong drug safety strategy. The 3rd Edition of Pharmacovigilance is organised in this light of background. Pharmacovigilance-2014 conference is being collaborated with Society of Pharmacovigilance, India . This educational 3 day conference will provide a unique platform for learning and networking.
Some of the subjects and issues that will be deliberated during the meet include: Pharmacovigilance and its Challenges; Role of Clinical Trials; Clinical Trials on Diseases; Adverse Drug Reactions; Pharmacokinetics and Pharmacodynamics; Pharmacy Practices and its Challenges; Risk Management: New Approaching Paradigm for Pharmacovigilance; Clinical Research and Statistics; Strategies for Growth in Pharma Environment; Good Pharmacovigilance Practice and Pharmacoepidemiology; Case Report in Clinical Trials and others.
Indian Pharmaceutical industry is worth more than Rs. 90,000 crores and it is growing at the rate of 12 - 14% per annum. India is the Global Clinical trial hub and there is simultaneous global introduction of new medicines. Clinical data mining and signal detection associated with pharmacovigilance technology contribute to potential benefits in providing safe and secured drug administration and public health. In the wake of Hyderabad attaining a centre place as a pharmaceutical hub, OMICS Groups 3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials attains significance.
India is home for more than half a million qualified doctors and 15,000 hospitals having bed strength of 6, 24,000 and it is the fourth largest producer of pharmaceuticals in the world. According to various estimates, Adverse Drug Reactions occur in 10-20% of hospital inpatients, accounting for 2-6 % of all hospital admissions, and are among top 10 causes of death in inpatients. Overall incidence of Adverse Drug Reaction (ADR) is about 6.7 % and 0.32 %. 15-20% of hospital budget may be spent dealing with fatal drug complications. 30% to 60% of ADRs are preventable. More than 121 médecines have been withdrawn to endure public safety for the past 40 years.
Extensive use of animal and human for the drug research in the name of Clinical trial is equally contravercial where animals are subjected to risk for testing the new drugs. Incomplete information is often provided for the patient that volunteers for Clinical Trials. Keeping the national as well as global pharmaceutical industry growth, OMICS Group International announces its 3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials during October 27-29, 2014 at Hyderabad International Convention Centre (HICC), Hyderabad, India with a theme "Safer Drugs to Market by Analyzing Latest Developments in Pharmacovigilance, Drug Safety and Risk Management".
OMICS Group International contributes to the scientific community through its Open Access Initiative and OMICS Group Conferences. OMICS Group hosts over 400 leading-edge peer reviewed Open Access Journals which are supported by more than 30000 eminent Editorial Board Members. OMICS Publishing Group journals enjoy the readership of 3.5 million people and organize over 300 International Conferences annually all over the world with the support of more than 1000 scientific associations. OMICS Group Conferences conducts Scientific Conferences, symposia, workshops, trade shows, exhibitions and world science congresses by bringing together people on a single platform and thereby achieving its goal of widening the knowledge base across the world.
Reference: Solus Media